Investing.com - BioLife Solutions (NASDAQ:BLFS) reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. BioLife...
BioLife Solutions (BLFS) reported Q3 EPS of ($0.23), $0.07 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $40.7 million versus the consensus...
SmileDirectClub (NASDAQ:SDC), Inc. SDC is scheduled to report first-quarter 2020 results on May 13, after the closing bell.SmileDirectClub has a negative earnings surprise of...
Daqo New Energy Corp. (NYSE:DQ) is set to release fourth-quarter 2019 results ahead of the bell on Mar 11. Benefits of higher production and sales volumes are likely to reflect...
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
|Average||31.38 (+67.96% Upside)|
|No. of Analysts||8|